Hepion Pharmaceuticals (FRA:336) Net Income (Continuing Operations) : €-35.63 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hepion Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was €-2.63 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €-35.63 Mil.

Hepion Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Hepion Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Net Income (Continuing Operations) Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-6.33

-16.73

-28.96

-39.84

-44.87

Hepion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-12.39	-13.00	-9.86	-10.14	-2.63

Hepion Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-35.63 Mil.

Hepion Pharmaceuticals (FRA:336) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Hepion Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

HEPA:USA

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines